Artificial Vital Organs and Medical Bionics Market
P
2024
The global artificial vital organs and medical bionics market was valued at $47.4 billion in 2023, and is projected to reach $99.0 billion by 2033, growing at a CAGR of 7.6% from 2024 to 2033. Increasing prevalence of chronic diseases, surge in demand for organ transplants is the driving factor for the market growth.
Artificial organs and bionic implants are medical devices designed to replace or augment the function of natural organs or body parts that are damaged, dysfunctional, or missing. These devices utilize advanced technology and engineering principles to restore or enhance bodily functions, improve quality of life, and provide therapeutic benefits to individuals with medical conditions or disabilities. Artificial organs are man-made devices that replicate the structure and function of specific organs in the body. Bionic implants, on the other hand, are electronic or mechanical devices that are implanted within or attached to the body to enhance or restore specific functions. Bionic implants combine biological and technological elements to interface with the body's natural systems and provide additional capabilities.
The artificial vital organs and medical bionics market growth is influenced by the increasing demand for organ transplants. There is a persistent shortage of donor organs worldwide, leading to long waiting lists and high mortality rates among patients awaiting transplants. Artificial vital organs and medical bionics provide an alternative solution to bridge this gap and reduce dependency on scarce donor organs. In addition, rapid advancements in materials science, biotechnology, and robotics have significantly enhanced the capabilities and functionalities of artificial vital organs and medical bionics.
Improved biocompatibility, durability, and functionality are making these devices more viable and effective in clinical settings and are the artificial vital organs and medical bionics market opportunity. Moreover, the aging population is highly susceptible to diseases owing to organ failure coupled with reduced reserve capacity in their organs and decline in organ function, which drives the growth of the artificial organs market size.
Artificial organs and bionic implants can play a crucial role in the treatment and rehabilitation of individuals who have experienced trauma or accidents. Therefore, rise in cases of road accidents and injuries resulting in the loss or amputation of limbs increases the demand for artificial organs and bionic implants. Hence, such types of factors drive the artificial vital organs and medical bionics market forecast
Furthermore, chronic diseases such as cardiovascular diseases, diabetes, kidney failure, and respiratory disorders are on the rise globally. Artificial vital organs and medical bionics offer therapeutic options for managing these conditions, improving patient outcomes, and enhancing quality of life. Thus, the aforementioned factors are anticipated to drive the artificial vital organs and medical bionics market share.
Although the growth of artificial vital organs and medical bionics size has been more rapid in recent years, the industry can draw on the patents filed by various companies. For instance, patents filed by the companies based in U.S. dominated the same with 40.8% share, Patent Cooperation Treaty (PCT) , holds a share of about 17.7%, China holds a share of about 25.6% and other countries held a share of about 10%.
The artificial vital organs and medical bionics market is segmented into type, technology, end user, and region. Based on type, the market is categorized into artificial organs and medical bionics. The artificial organs is further segmented into artificial heart, artificial kidney, artificial lungs and others. The medical bionics is further segmented into orthopedic bionics and others. Based on technology the market is bifurcated into mechanical and electronic. Based on end users, the market is classified into hospitals, ambulatory surgical centers, and others. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
North America accounted for a major artificial vital organs and medical bionics market share owing to advanced healthcare infrastructure, robust research and development capabilities, strong regulatory frameworks, and significant investment. These factors, combined with strong presence of major key players, contribute to the region’s leading position in the market. Also rise in the number of clinical trials; and high healthcare expenditure from the government organizations in the region drive the growth of the market.
Asia-Pacific artificial vital organs market is estimated to grow with the highest CAGR during the forecast period, owing to increasing healthcare investments, and government initiatives. Also rise in road accidents and injuries as well as increase in purchasing power in populated countries, such as China and India. The countries in Asia-Pacific possess a huge population base and increasing geriatric population boosting the market.
The major players operating in the artificial vital organs and medical bionics industry include SynCardia Systems LLC, Abbott Laboratories, Cochlear Limited, Boston Scientific Corporation, Johnson & Johnson, Edwards Lifesciences Corporation, Zimmer Biomet Holding Inc., Berlin Heart GmbH, Jarvik Heart, Inc., and Medtronic plc.
In September 2021, Picard Medical, Inc (“Picard”) , a portfolio company of Hunniwell Lake Ventures, LLC, announced that it had acquired SynCardia Systems, LLC, the global leader in mechanical heart replacement technology and solution provider.
National Center for Biotechnology Information
World Health Organization (WHO)
National Library of Medicine
The United States Food and Drug Administration
U.S. Department of Health & Human Services
Centers for Disease Control and Prevention
Aspect | Details |
---|---|
![]() Market Size By 2033 | USD 99.0 Billion |
![]() Growth Rate | CAGR of 7.6% |
![]() Forecast period | 2024 - 2033 |
![]() Report Pages | 280 |
By Type |
|
By Technology |
|
By Region |
|
Key Market Players | SynCardia Systems LLC, Johnson & Johnson, Medtronic Plc., Berlin Heart GmbH, Jarvik Heart, Inc., Cochlear Limited, Zimmer Biomet Holding Inc., Edwards Lifesciences Corporation, Abbott Laboratories, Inc., Boston Scientific Corporation |
Increase in demand for organ transplants are the upcoming trends of Artificial Vital Organs and Medical Bionics Market in the globe
Hospitals are the leading of End User Artificial Vital Organs and Medical Bionics Market
North America is the largest regional market for Artificial Vital Organs and Medical Bionics
The artificial vital organs and medical bionics market was valued at $47.40 billion in 2023.
The major players operating in the artificial vital organs and medical bionics market include SynCardia Systems LLC, Abbott Laboratories, Cochlear Limited, Boston Scientific Corporation, Johnson & Johnson, Edwards Lifesciences Corporation, Zimmer Biomet Holding Inc., Berlin Heart GmbH, Jarvik Heart, Inc., and Medtronic plc.